Patent Grant
11331221
The subject matter disclosed herein relates generally to negative pressure dressings and to negative pressure tissue treatment devices having negative pressure dressings and, more particularly, to dressings that can be used with a source of negative pressure to deliver negative pressure therapy. Such dressings are suitable for the treatment of a variety of wounds including chronic and acute types, including infected wounds, venous ulcers, diabetic ulcers, burns, surgical wounds and the like.
Clinical studies and practice have shown that providing a negative pressure in proximity to a tissue site augments and accelerates the growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but one particular application of negative pressure involves treating wounds. This treatment (frequently referred to in the medical community as “negative pressure wound therapy,” “reduced pressure therapy,” or “vacuum therapy”) provides numerous benefits, including drawing out fluid from the wound, migration of epithelial and subcutaneous tissues, improved blood flow, and micro-deformation of tissue at the wound site. These benefits result in increased development of granulation tissue and faster healing times, while also helping to reduce the level of scar formation. Typically, negative pressure is applied by a reduced pressure source to tissue through a porous pad or other manifold device that is sealed to a patient's skin around the periphery of a wound or other tissue for which such treatment is prescribed. The porous pad includes cells or pores that are capable of distributing reduced pressure to the tissue and channeling fluids that are drawn from the tissue. The porous pad often is incorporated into a dressing having other components that facilitate treatment.
In the administration of negative pressure wound therapy, the negative pressure may be applied continuously or intermittently, depending on the type of wound or other tissue being treated and the clinical objectives. The dressing can be changed periodically, such as, for example, one, two, or three times per week (or as needed). The terms “reduced pressure” and “negative pressure” refer to a pressure that is below normal atmospheric pressure.
To enable a prolonged application of topical negative pressure, powered systems, which include a vacuum generation source such as a pump, have been developed. Many of these systems, however, are not convenient for users as they can be large, heavy, noisy, uncomfortable, and not simple for users to apply and operate correctly. Such systems also rely on an outside power or vacuum source to create the prescribed negative pressure conditions.
Negative pressure wound and tissue treatments and other advanced technical interventions are becoming more prevalent given the occurrence of both the aging population, as well as the increasingly compromised patient populations. This trend looks set to continue. In wound care, healthcare professionals are now more likely to encounter wounds that are difficult to manage with a multitude of complex healing problems.
While several approaches have been used in the application of negative pressure therapy for the management of wounds, these suffer from multiple issues. For example, one problem with negative pressure wound dressings in the prior art is that they often experience leaks around the dressing periphery. Relatedly, negative pressure wound dressings that experience leaks require more powerful pumps, which in turn require substantially greater inputs of energy, typically electrical energy, to maintain an acceptable amount of pressure reduction at the wound site. Another problem with such dressings relate to the dressing's inability to absorb and retain acceptable quantities of drainage and exudate from the wound site to promote an adequate environment for healing. Moreover, many prior art negative pressure wound dressings are provided as a set of multiple parts or components that require assembly via multiple application steps at the time the dressing is being applied over the wound, which often results in improper applications of the dressing and/or inoperability of the device. All of these problems detract from the effectiveness of the prescribed negative pressure wound therapy, resulting in a suboptimal wound healing environment.
There remains a need for negative pressure wound dressings that are simple to apply to a wound site, that are provided in the form of a unitary dressing construct and that provide improved sealing for maintenance of acceptable negative pressure at the wound site with decreased power requirements. The present disclosure addresses these needs and provides other benefits and advantages.
The present disclosure provides negative pressure wound dressings, and devices that include negative pressure wound dressings. In one aspect of the disclosure, there is provided a unitary negative pressure wound dressing construct that includes: (i) an absorbent layer having a first surface for contacting a wound and a second surface opposite the first surface, the absorbent layer comprising a gelling absorbent material and having a perimeter border, (ii) a cover layer having a first surface facing the absorbent layer and a second surface opposite the first surface, wherein the cover layer has a perimeter border having dimensions greater than the dimensions of the absorbent layer perimeter such that the perimeter border of the cover layer extends beyond the perimeter border of the absorbent layer, and (iii) a peripheral adhesive skin contact layer attached to the first surface of the absorbent layer adjacent the perimeter border of the absorbent layer, wherein the peripheral adhesive skin contact layer defines a window through which the absorbent layer is able to contact the wound, and wherein the peripheral adhesive skin contact layer comprises a hydrocolloid adhesive. In some embodiments, the dimensions of the perimeter border of the absorbent layer are greater than dimensions of a wound to be covered by the dressing. In some embodiments, wherein the cover layer is water impermeable. In some embodiments, the cover layer is water impermeable and air and vapour permeable. In some embodiments, the peripheral adhesive skin contact layer has a perimeter border having dimensions greater than the dimensions of the absorbent layer perimeter such that the perimeter border of the peripheral adhesive skin contact layer extends beyond the perimeter border of the absorbent layer. In some embodiments, the perimeter border of the cover layer and the perimeter border of the peripheral skin contact layer are bonded together to form a seal. In some embodiments, the peripheral adhesive skin contact layer is operable to adhere to skin surrounding a wound. In some embodiments, the cover layer defines an aperture configured for connection to a source of negative pressure.
In some embodiments, the peripheral adhesive skin contact layer and the cover layer are operable to form an air-tight seal between the absorbent layer and an external environment of the dressing when the dressing is applied over a wound and a source of negative pressure is sealingly connected to the aperture. In some embodiments, the peripheral adhesive skin contact layer has a thickness of from about 0.1 mm to about 5 mm. In some embodiments, the peripheral adhesive skin contact layer has a width of from about 2 cm to about 6 cm.
In some embodiments, the dressing further includes a first bonding layer positioned between the absorbent layer and the cover layer. In some embodiments, the first bonding layer comprises a layer of hydrocolloid adhesive. In some embodiments, the first bonding layer has a thickness of from about 0.2 mm to about 2 mm.
In some embodiments, the dressing further includes a structural layer corresponding to the peripheral adhesive skin contact layer and having a first surface bonded to the peripheral adhesive skin contact layer, and a second bonding layer corresponding to the peripheral adhesive skin contact layer and positioned in contact with a second surface of the structural layer that is opposite the first surface of the structural layer. In some embodiments, the structural layer is positioned between, and sealingly bonded to, the peripheral adhesive skin contact layer and the second bonding layer. In some embodiments, the second bonding layer is sealingly bonded to a continuous portion of the first surface of the absorbent layer that is adjacent the full perimeter border of the absorbent layer. In some embodiments, the peripheral adhesive skin contact layer, the second bonding layer and the cover layer are operable to form an air-tight seal between the absorbent layer and an external environment of the dressing when the dressing is applied over a wound and a source of negative pressure is sealingly connected to the aperture. In some embodiments, the structural layer comprises a polyurethane film. In some embodiments, the second bonding layer has a thickness of from about 0.2 mm to about 2 mm.
In some embodiments, the dressing further includes a first bonding layer positioned between the absorbent layer and the cover layer, a structural layer corresponding to the peripheral adhesive skin contact layer and having a first surface bonded to the adhesive skin contact layer, and a second bonding layer corresponding to the peripheral adhesive skin contact layer and positioned in contact with a second surface of the structural layer that is opposite the first surface of the structural layer. In some embodiments, the structural layer is positioned between, and sealingly bonded to, the peripheral adhesive skin contact layer and the second bonding layer. In some embodiments, the second bonding layer is sealingly bonded to a continuous portion of the first surface of the absorbent layer that is adjacent the full perimeter border of the absorbent layer.
In some embodiments, the gelling absorbent material comprises a gel-forming fiber or filament. In some embodiments, the gel-forming fiber or filament comprising chemically-modified cellulose, alginate, carboxymethyl cellulose, or combinations thereof. In some embodiments, the absorbent layer comprises stitches. In some embodiments, the absorbent layer further comprises an antimicrobial agent. In some embodiments, the cover layer comprises a member selected from the group consisting of a polyurethane (PU), a polyvinyl chloride (PVC), a silicone elastomer, a fluoropolymer, and combinations thereof.
In some embodiments, the dressing further includes a source of negative pressure sealingly connected to the aperture and in fluid communication with the absorbent layer. In some embodiments, the source of negative pressure comprises a pump connected to the aperture. In some embodiments, the pump is connected to the aperture with a conduit. In some embodiments, the dressing further includes a connector attached to the cover layer over the aperture and configured for connection to a conduit to communicate negative pressure from the conduit to the wound through the aperture. In some embodiments, the connecter comprises polyurethane or polyvinylchloride. In some embodiments, the connecter comprises a change indicator.
In some embodiments, the dressing further includes a negative pressure distribution layer positioned between the absorbent layer and the cover layer. In some embodiments, the negative pressure distribution layer comprises an open cell foam layer. In some embodiments, the open cell foam layer is hydrophobic.
In another aspect of the disclosure, there is provided a disposable negative pressure wound therapy device that includes a disposable pump for generating negative pressure, and a dressing according to any of the embodiments disclosed herein for covering and protecting a wound, wherein the cover layer defines an aperture connected to the pump. In some embodiments, the disposable pump is a battery operated pump. In some embodiments, the device further includes a conduit defining a lumen that provides fluid communication between the pump and the aperture defined in the cover layer of the dressing, whereby operation of the pump creates negative pressure at the site of a wound when the dressing is affixed over the wound by pressure sealing the peripheral adhesive skin contact layer to skin surrounding the wound.
Further features, characteristics and embodiments of the present disclosure will be apparent from the detailed description herein.
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
It should be understood that the drawings are not necessarily to scale and that the disclosed embodiments are sometimes illustrated diagrammatically and in partial views. In certain instances, details which are not necessary for an understanding of the disclosed methods and devices or which render other details difficult to perceive may have been omitted. It should be further understood that this disclosure is not limited to the particular embodiments illustrated herein.
For the purposes of promoting an understanding of the principles of the invention, reference will now be made to the embodiments described herein and illustrated in the Figures and specific language will be used to describe the same. The embodiments of the present application described below are not intended to be exhaustive or to limit the teachings of the present application to the precise forms disclosed in the following detailed description. Rather, the embodiments are chosen and described so that others skilled in the art may appreciate and understand the principles and practices of the present application. It will therefore be understood that no limitation of the scope of the invention is intended by the description of specific embodiments. Any alterations and further modifications in the described embodiments, and any further applications of the principles of the invention as described herein are contemplated as would normally occur to one skilled in the art to which the invention relates.
Problems and challenges associated with negative pressure wound dressings in the prior art, such as poor seals, complex on-site assembly and the like are addressed by the present disclosure, which provides new negative pressure wound dressing constructs that feature unitary construction with strong seals and excellent fluid absorption characteristics.
One aspect of the disclosure is a dressing that includes an absorbent layer comprising a gelling absorbent material, a cover layer composed of a water impermeable and air and vapour permeable material overlying the absorbent layer, and a peripheral adhesive skin contact layer situated beneath the peripheral border of the absorbent layer to sealingly affix the dressing to a patient's skin. As used in the above sentence, the term “beneath” means “on the opposite side from the skin cover layer.” The peripheral adhesive skin contact layer comprises a hydrocolloid adhesive. The cover layer defines an aperture configured for connection to a source of negative pressure.
The dressings disclosed herein are particularly suitable for use in vacuum and/or negative pressure wound therapy, but can alternatively be used in other contexts as well, including but not limited to use in other exudate or fluid producing instances.
Vacuum wound therapy can be used for the treatment of a multitude of wound types, including but not limited to, acute wounds (such as, following fasciotomy or other surgeries), chronic wounds (such as pressure ulcers, trophic and vascular ulcers), and the management of complex soft tissue injuries (such as, open abdomen (laparotomy)).
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the subject matter of this disclosure belongs. Moreover, it should be understood that when certain values and ranges are recited herein in connection with various embodiments of the present teachings, all values and ranges which fall between such listed values and ranges are intended to be encompassed by the present teaching unless explicitly stated otherwise. Finally, although specific methods and materials are described herein with respect to certain representative aspects of the present disclosure, it should be understood and appreciated that other methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application without straying from the intended scope of this disclosure.
It is to be understood that the following general description and the following examples are explanatory only and are not restrictive of any subject matter claimed. It is also to be understood that, while the use of words such as preferable, preferably, preferred or more preferred utilized in the description above indicate that the feature so described may be more desirable, it nonetheless may not be necessary and embodiments lacking the same may be contemplated as within the scope of the invention, the scope being defined by the claims that follow. In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, use of the terms “comprising,” “including” and “having,” as well as other forms, such as “comprise,” “comprises,” comprised,” “include,” “includes,” “included,” “have” and “has” are inclusive and not limiting, and therefore specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. The method actions, processes, and operations described herein are not to be construed as necessarily requiring their performance in the particular order discussed or illustrated, unless specifically identified as an order of performance. It is also to be understood that additional or alternative actions or operations may be employed.
Although the terms first, second, third, etc. may be used herein to describe various elements, components, regions, layers and/or sections, these elements, components, regions, layers and/or sections should not be limited by these terms. These terms may be only used to distinguish one element, component, region, layer or section from another region, layer or section. Terms such as “first,” “second,” and other numerical terms when used herein do not imply a sequence or order unless clearly indicated by the context. Thus, a first element, component, region, layer or section discussed herein could be termed a second element, component, region, layer or section without departing from the teachings of the example embodiments.
As used herein, ranges and amounts can be expressed as “about” a particular value or range. About also includes the exact amount. For example, “about 5 μL” means “about 5 μL” and also “5 μL.” Generally, the term “about” includes an amount that would be expected to be within experimental error. The term “about” includes values that are within 10% less to 10% greater of the value provided. For example, “about 50%” means “between 45% and 55%.” Also, by way of example, “about 30” means “between 27 and 33.”
The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
As used herein, the terms “individual(s)”, “subject(s)” and “patient(s)” mean any mammal. In some embodiments, the mammal is a human. In some embodiments, the mammal is a non-human.
The term “exudate” refers to any fluids produced by a wound that may be secreted from the wound.
The term “periwound” refers to the area directly bordering the wound area itself. The term “periskin” refers to the skin area directly bordering the wound area itself.
The terms “negative pressure” and “reduced pressure” as used herein generally refer to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure associated with tissue at the tissue site. Although the terms “vacuum” and “negative pressure” may be used to describe the pressure applied to the tissue site, the actual pressure reduction applied to the tissue site may be significantly less than the pressure reduction normally associated with a complete vacuum.
As used herein, the term “moldable” refers to an elastic, deformable property and ability to conform and/or form a seal. The moldable materials of various embodiments disclosed herein may be differentiated from stretchable and flexible materials. The term, “moldable” can encompass the properties of malleability and ductility. The absolute shape change of a moldable material may be controlled by an external resistive element resulting in conformance to a complimentary feature.
As used herein, the term “flexible” refers to the elastic deformation of a structure under an external force. Upon removal of the external force the structure will substantially return to its original (previous) geometry. Measurement of flexibility can be quantified in linear displacement (μm, mm, cm, m), e.g., original length/diameter and flexed length/diameter. The second moment of area influences the deformation experienced by the body. A device which is moldable can also have the property of flexibility. Flexibility is desirable in dressings. Skin flexes during the movement and activities of daily living, especially in areas over joint tissues. Rigid systems would not be able continually adapt to the skin flexibility. However, flexible devices are capable of continually adapting to the skin and mucosal membranes flexibility.
The general term “adhesive,” as used herein, refers to layers, fabrics, strips, laminates, barriers and materials that are used to promote adherence of a dressing to the skin and/or promote a seal between layers of the dressing to one another, thereby preventing undesirable leakage of effluent and providing an effective environment for application of negative pressure.
Several representative embodiments of dressings suitable for use in connection with negative pressure wound therapy are described herein. First with reference to
In some embodiments, first surface 122 of cover layer 120 is bonded to first surface 114 of absorbent layer by an adhesive. In other embodiments, at least a portion of cover layer 120 adjacent its perimeter 126 is bonded to a portion of absorbent layer 110 adjacent its perimeter 116. In some embodiments, first surface 122 of cover layer 120 is bonded to first surface 114 of absorbent layer by positioning a bonding layer between absorbent layer 110 and cover layer 120. In some embodiments the bonding layer comprises an adhesive. In some embodiments, the bonding layer comprises a layer of hydrocolloid adhesive.
Dressing 100 is configured to be held in place over a wound by peripheral skin contact layer 130, which extends around the border of the dressing and defines a window therethrough. Peripheral adhesive skin contact layer 130 is composed of a material that is capable of durably and strongly adhering to skin to form a seal. The durability of the dressing's adherence to a patient's skin is an important factor in the prevention of an unacceptable level of leakage during application of negative pressure wound therapy. A person of ordinary skill understands that such durability is directly proportional to the properties of the composition used to make the peripheral skin contact layer 130, which impacts the strength of adherence between the peripheral adhesive skin contact layer and underlying skin, and also is directly proportional to the width W1 of peripheral adhesive skin contact layer 130. In one embodiment, peripheral adhesive skin contact layer 130 has a width of from about 1 cm to about 10 cm. In another embodiment, peripheral adhesive skin contact layer 130 has a width of from about 2 cm to about 6 cm. In still another embodiment, peripheral adhesive skin contact layer 130 has a width of from about 2 cm to about 5 cm
Peripheral adhesive skin contact layer 130 and cover layer 120 are operable to form an air-tight seal between the absorbent layer and an external environment of dressing 100 when dressing 100 is applied over a wound and a source of negative pressure is sealingly connected to aperture 128.
When dressing 100 (or any other dressing disclosed herein) is manufactured, a removable film, referred to herein as a “removable backing” (not shown) may be adhered to an outer surface (also referred to as “bottom surface”) of peripheral adhesive skin contact layer 130, which removable backing is to be removed before use of dressing 100. With reference to
Absorbent layer 110 is composed of a gelling absorbent material. The gelling absorbent material preferably is capable of absorbing exudate from a wound and allowing passage of fluid through it. Absorbent layer 110 may have an open weave structure with pockets available for fluid absorption. In other embodiments, the absorbent layer may be nonwoven, knitted or formed of a tight weave. In some embodiments, the absorbent layer is a nonwoven. The absorbent layer can expand upon absorption of exudate or other fluid produced from the wound site.
In some embodiments, the absorbent layer comprises a gel-forming fiber, filament, or agent. In some embodiments, the gel-forming fiber or filament is chemically-modified cellulose, alginate, or carboxymethyl cellulose, or a combination thereof. In some embodiments, the gel-forming fiber is carboxymethyl cellulose. The absorbent layer also can include other absorbent materials such as, for example, polyacrylate, polyacrylate fibers, bi-component superabsorbent fibers, air laid nonwovens, needlefelt nonwovens, thermobonded nonwovens and foams.
Some formulations of the absorbent layer contain an alginate to increase absorption capabilities. The active surface of the absorbent layer can be coated with a cross-linked adhesive mass containing a dispersion of gelatin, pectin and/or carboxymethyl cellulose together with other polymers. In contact with traditional dressings, the polysaccharides and other polymers absorb water and swell, forming a gel. The moist conditions produced under the dressing are intended to promote fibrinolysis, angiogenesis and wound healing, without causing softening and breaking down of tissue.
Absorbent layer 110 preferably comprises gel forming fibres. By gel forming is meant hygroscopic fibres which upon the uptake of wound exudate become moist slippery or gelatinous and thus reduce the tendency for the surrounding fibres to adhere to the wound. The gel forming fibres can be of the type which retain their structural integrity on absorption of exudate or can be of the type which lose their fibrous form and become a structureless gel. The gel forming fibres are preferably spun sodium carboxymethylcellulose fibres, chemically modified cellulosic fibres, pectin fibres, alginate fibres, chitosan fibres, hyaluronic acid fibres, or other polysaccharide fibres or fibres derived from gums. The gel forming fibres are preferably sodium carboxymethylcellulose fibres, chemically modified cellulosic fibres, alkyl sulphonate modified cellulosic fibres such as those described in WO2012/061225, pectin fibres, alginate fibres, chitosan fibres, hyaluronic acid fibres, or other polysaccharide fibres or fibres derived from gums. The gel forming fibres are preferably chemically modified cellulosic fibres in the form of a fabric and in particular carboxymethylated cellulose fibres as described in PCT WO00/01425 to Azko Nobel UK Ltd. The cellulosic fibres preferably have a degree of substitution of at least 0.05 carboxymethyl groups per glucose unit. In another embodiment, the cellulosic fibres have a degree of substitution of from about 0.12 to about 0.35 as measured by IR spectroscopy (as defined in WO 00/01425). In another embodiment, the cellulosic fibres have a degree of substitution of from about 0.20 to about 0.30 and are made by carboxymethylating a woven, knitted, or non-woven cellulosic fabric such that the absorbency is increased. The gel forming fibres preferably have an absorbency of at least 2 grams 0.9% saline solution per gram of fibre (as measured by the free swell method).
Preferably the gel forming fibres have an absorbency of at least 10 g/g as measured in the free swell absorbency method, more preferably, between 15 g/g and 25 g/g.
The gelling absorbent material can be made in accordance with the disclosure of WO 93/12275, which describes the production of various absorbent carboxymethylated cellulosic products that are capable of absorbing many times their own weight of water. This causes the carboxymethylated fibres to form a gel. WO 94/16746 and WO 00/01425 describe the use of carboxymethylated Lyocell materials in wound dressings where the advantages of gel formation in preventing adherence and therefore reducing wound damage and pain on removal are described.
Carboxymethylation can be achieved, for example, by sequential or simultaneous treatment of the cellulosic material with a strong alkali, such as aqueous sodium hydroxide, and monochloroacetic acid or a salt thereof. The appropriate reaction conditions will depend upon the composition of the fabric and the degree of carboxymethylation required and will be readily apparent to the person skilled in the art. They may be identical or similar to those described in WO 93/12275, WO 94/16746 or WO 00/01425. Desirably the carboxymethylation is carried out in the presence of industrial methylated spirits (IMS), and IMS is preferably also used in a subsequent washing step, suitably along with water, as a cleaner and steriliser. The degree of carboxymethylation is desirably such that upon absorption of exudate the fibres at the skin-contacting surface of the bandage form a gel.
In some embodiments, absorbent layer 110 comprises carboxymethylated cellulose fibres formed into a fabric. In other embodiments, absorbent layer 110 comprises two or more layers of fabric comprising carboxymethylated cellulose fibres. In one embodiment, absorbent layer 110 comprises from about two to about ten layers of fabric comprising carboxymethylated cellulose fibres. In another embodiment, absorbent layer 110 comprises from about two to about eight layers of fabric comprising carboxymethylated cellulose fibres.
In one embodiment in which absorbent layer 110 comprises one or more layers of fabric comprising carboxymethylated cellulose fibres, absorbent layer 110 further comprises stitching to increase the tensile strength and/or the resilience of dressing 100. In an absorbent layer that includes more than one layer of fabric comprising carboxymethylated cellulose fibres, the stitching can be present in only one or in more than one fabric layer. In one embodiment stitching is present in the fabric layer that is positioned to contact the wound in use of dressing 100.
Stitching contemplated by this disclosure can include inelastic threads or yarns and/or resilient thread or yarn. WO 2007/003905 describes dressings in which stitching is used to increase the tensile strength of dressings, which are particularly suitable for use in dressing burns. U.S. Pat. No. 10,117,783 describes dressings in which stitching is used to increase the resilience of dressings, which are particularly suitable for use in dressings placed on body positions were movement occurs, such as joints (e.g., elbows, knees, hips, etc.) or abdomen.
By resilient is meant that the yarn or thread is able to extend and contract to its former shape. The gathers in the absorbent layer formed by the resilient thread or yarn, enable the absorbent layer to extend and contract with movement so that when, for example, the patient's leg is bent the dressing stretches and when the leg is straightened, the dressing recovers its former size. This resilience means that the absorbent layer maintains close conformability with the wound during movement of the patient. It also means that the dressing has a reduced tendency to delaminate during wear. Having the ability to stretch means that there is less movement between the dressing and the patient which enables a more durable seal between the dressing and the patient's underlying skin.
Preferably the absorbent layer further comprises lines of longitudinal warp stitches formed from an inelastic thread which stitching is longitudinal in that it is generally parallel to the long dimension of the absorbent layer. The warp stitches are preferably made in the absorbent layer after it has been formed.
The inelastic warp stitching preferably passes through the whole thickness of the absorbent layer and is visible on both sides. The absorbent layer preferably comprises two or more layers of fabric that are layered together and stitch bonded with lines of longitudinal inelastic warp stitches. The resilient thread is preferably woven in between the stitches of the inelastic warp stitching and in between the sheets of fabric. By having two layers of fabric it is possible to hold the resilient thread or yarn out of direct contact with the wound.
The resilient thread gathers the absorbent layer and enables it to elongate and then return to shape. The resilient thread can be stitched through the absorbent layer to gather the dressing or woven through a separate line of inelastic warp stitches. The resilient thread can be stitched through the absorbent layer in lines of longitudinal stitches 1 mm to 10 mm apart, more preferably 2 mm to 5 mm apart. The resilient thread is preferably applied to the absorbent layer after the absorbent layer has been formed.
The lines of inelastic warp stitching may be from 1 mm to 10 mm apart and preferably from 2 mm to 5 mm apart. The lines of inelastic stitching are typically crocheted or knitted and have the appearance of a chain stitch but other stitch patterns may also be used. Preferably, the lines of resilient stitching gather the absorbent layer so that the absorbent layer is able to elongate by 25% to 85%, more preferably 35% to 75% and most preferably 40% to 70% and then recover even when the absorbent layer is hydrated. More preferably, the lines of warp stitching are made in a yarn or thread such as nylon or polyester or Tencel® (Lenzing Aktiengesellschaft) or any thread which is strong and easily processed. The resilient stitches are made in a resilient yarn such as an elastomeric yarn or Lycra or other yarn which has good stretch and recovery or an elastane yarn which is an elastomeric yarn with greater than 85% polyurethane such as Lycra® (The Lycra Company) or Spandex.
In one representative way of making absorbent layer 110, it is made from a non-woven roll made by forming a web of Lyocell which is then hydroentangled. The web is then carboxymethylated by sequential or simultaneous treatment of the cellulosic material with a strong alkali, monochloroacetic acid or a salt thereof. Two webs of the resulting fabric are then fed into a stitch bonding machine and stitched simultaneously with lines of longitudinal stitching in an inelastic yarn and a resilient yarn woven in between the stitches and so secured at the centre of the webs. The resilient yarn gathers the absorbent layer (not shown) and is carried by the inelastic stitch bonded yarn. The resulting layer has a basis weight of 350 gm−2.
In another representative way of making absorbent layer 110, it is made from a tow of carboxymethyl cellulose filaments which has been needlefelted. Two webs of the needlefelted tow are fed into a stitch bonding machine and stitched simultaneously with lines of longitudinal stitching in inelastic yarn and with a resilient yarn woven in between the stitches and so secured at the centre of the webs.
In one embodiment, absorbent layer 110 is provided with fenestrations to aid the application of negative pressure to the wound and maintain the pathway for fluid from the wound, through the absorbent layer. Typically, however, fenestrations are only provided in internal absorbent layers. External absorbent layers, including those in direct contact with the wound, generally do not have mechanically added fenestrations, however, they do have openings between the fibres.
Absorbent layer 110 may comprise one or more medicaments. For example an antimicrobial agent, or an antibiotic, or an anaesthetic on an anti-inflammatory agent or a skin protective agent or an odour absorbing agent. In some embodiments, the absorbent layer comprises an antimicrobial agent that can inhibit the growth of gram negative bacteria and/or gram positive bacteria. The antimicrobial agent can kill microbes, inhibit microbes' growth cycle, or disrupt the formation of microbial biofilms. Antimicrobial agents inhibit the growth of bacteria and thus, promote healthy wound healing.
Cover layer 120 may be any material that provides a fluid seal. A fluid seal is a seal adequate to maintain reduced pressure at a desired site given the particular reduced pressure source or subsystem involved. The cover layer may be, for example, an impermeable or semi-permeable, elastomeric material. For semi-permeable materials, the permeability must be low enough that for a given reduced-pressure source, the desired reduced pressure may be maintained. The cover layer may be waterproof. In some embodiments, the cover layer comprises polyester, polyurethane (PU), polyvinyl chloride (PVC), silicone elastomer, or fluoropolymers. In some embodiments, the cover layer may comprise polyester or polyurethane film.
Cover layer 120 is adapted to enable negative pressure to be applied at the wound and defines an aperture therethrough configured for connection to a source of negative pressure. In one embodiment, the aperture comprises a port configured for attachment to a conduit that is, in turn, configured for attachment to a source of negative pressure. The dressing provides a fluid pathway from the wound, through the absorbent layer and the aperture to the conduit. The port is preferably located in that part of the cover layer that overlies the absorbent layer but towards the periphery of the absorbent layer so that it is not directly in vertical alignment with the centre of the dressing (or the wound when in use). This assists in the spread of exudate across the full extent of the absorbent layer.
In one embodiment, cover layer 120 of dressing 100 is a bacterial and viral barrier layer which preferably resists the ingress of liquid and air but allows moisture vapour transmission. In this way the outer cover layer enhances the overall fluid handling capacity of the dressing by allowing for the escape of moisture vapour through the cover while enabling the application of negative pressure to the wound. The outer cover layer is for instance a layer having a MVTR of at least 10,000 gm−2 per 24 hours or in the range of from 10,000 gm−2 to 50,000 gm−2 per 24 hours measured by the method described in BS EN 13726-2 2002 “Test methods for primary wound dressings Part 2 Moisture vapour transmission rate of permeable film dressings.”. The cover layer may be in the form of a film of polyurethane, for example Epurex 92 T/129 manufactured by Covestro or Inspire 2350 manufactures by Coveris or Medifilm 426 manufactured by Mylan.
Peripheral adhesive skin contact layer 130 may be of the type comprising a homogenous blend of one or more water soluble hydrocolloids and one or more low molecular weight polyisobutylenes such as are described in EP-B-92999 incorporated herein by reference. The water soluble hydrocolloids may be selected from sodium carboxymethylcellulose, pectin, gelatine, guar gum, locust bean gum, karaya gum, and mixtures thereof. The polyisobutylenes may be selected from low molecular weight polyisobutylenes having a viscosity average molecular weight of from 36,000 to 58,000 (Florey). The peripheral adhesive skin contact layer is capable of absorbing exudate while maintaining adhesion of the dressing to the skin.
Alternatively the adhesive composition may comprise a homogeneous blend of one or more hydrocolloids, one or more low molecular weight polyisobutylenes, one or more styrene block copolymers, mineral oil, butyl rubber, a tackifier and small amounts of optional components. By selection of specific ranges of the amounts of the above listed components, an adhesive composition may be prepared having good adhesion to the skin and stretchability. Such compositions and the preparation therefore are disclosed in EP-B-130061.
Preferably the composition of peripheral adhesive skin contact layer 130 is such that the removal of an adhesive wound dressing is not traumatic to the patient. Preferably the peripheral adhesive skin contact layer ensures a secure application of the dressing whist still permitting non-traumatic removal. Non-traumatic dressing removal may be facilitated by using an adhesive which gels slightly upon interaction with a fluid. The gel formation aids dressing removal.
The term, “hydrocolloid adhesive,” as used herein, refers to an adhesive material or substance that comprises a hydrocolloid. The formulation of these adhesives may be modulated to adjust physical properties of the material (e.g., its ability to create a vacuum seal, flexibility, breathability, comfort, size, etc.).
In some embodiments, the peripheral adhesive skin contact layer is at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, or at least 50% w/w hydrocolloid.
Peripheral adhesive skin contact layer 130 is operable to provide a seal between the peripheral adhesive skin contact layer and the skin, thereby preventing exudate leakage.
In some embodiments disclosed herein, the peripheral adhesive skin contact layer has a thickness of from about 0.1 mm to about 5 mm. In other embodiments, the skin contact layer has a thickness of from about 0.15 mm to about 3 mm. In yet other embodiments, the skin contact layer has a thickness of from about 0.2 mm to about 2 mm.
In other embodiments, additional structural layers and/or bonding layers are included in the dressing. With reference to
Absorbent layer 210 has first surface 212 for contacting a wound and second surface 214 opposite first surface 212, and has perimeter border 216 having dimensions greater than the dimensions of a wound to be covered by dressing 200. Cover layer 220 has first surface 222 facing absorbent layer 210 and has second surface 224 opposite first surface 222, and has perimeter border 226 that extends beyond perimeter border 216 of absorbent layer 210. As such, perimeter border 226 has dimensions greater than dimensions of perimeter border 216 of absorbent layer 210. Between first surface 222 of cover layer 220 and second surface 214 of absorbent layer 210 is positioned first bonding layer 240. Between peripheral adhesive skin contact layer 230 and first surface 212 of absorbent layer 210 adjacent its perimeter border 216 are situated structural layer 250 and second bonding layer 260, oriented such that structural layer 250 is adjacent to, and bonded to, peripheral adhesive skin contact layer 230, and second bonding layer 260 is situated between structural layer 250 and first surface 212 of absorbent layer 210, thereby bonding structural layer 250 to absorbent layer 210 in the area of peripheral border 216 of absorbent layer 210. Peripheral adhesive skin contact layer 230 has an inner edge 232 that coincides with inner edges of structural layer 250 and second bonding layer 260, together defining a window 234 through which first surface 212 of absorbent layer 210 is able to contact a wound over which dressing 200 is applied.
As shown most clearly in
In some embodiments, structural layer 250 comprises a polymer selected from, but not limited to, polypropyleneoxide, polyurethane, polyacrylate, ethylene vinyl acetate, and combinations thereof. In some embodiments, the polymer is formed into a thin film. In some embodiments, the structural layer comprises a polyurethane film.
In some embodiments, first bonding layer 240 comprises an adhesive. In some embodiments, bonding layer 240 comprises a hydrocolloid adhesive, for example Pectin, Gelatin, NaCMC—Sodium Carboxymethyl Cellulose. The adhesive may be at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, or at least 50% w/w hydrocolloid. First bonding layer 240 can be composed of the same hydrocolloid adhesive as peripheral adhesive skin contact layer 230 or can be composed of a different adhesive than peripheral adhesive skin contact layer 230.
In some embodiments, first bonding layer 240 has a thickness of from about 0.1 mm to about 5 mm. In some embodiments, first bonding layer 240 has a thickness of from about 0.2 mm to about 3 mm. In some embodiments, first bonding layer 240 has a thickness of from about 0.2 mm to about 2 mm. In some embodiments, first bonding layer 240 has a thickness of from 0.2 mm to about 1 mm.
In some embodiments, second bonding layer 260 comprises an adhesive. In some embodiments, second bonding layer 260 comprises a hydrocolloid adhesive, for example Pectin, Gelatin, NaCMC—Sodium Carboxymethyl Cellulose. The adhesive may be at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, or at least 50% w/w hydrocolloid. Second bonding layer 260 can be composed of the same hydrocolloid adhesive as peripheral adhesive skin contact layer 230 or can be composed of a different adhesive than peripheral adhesive skin contact layer 230.
In some embodiments, second bonding layer 260 has a thickness of from about 0.1 mm to about 5 mm. In some embodiments, second bonding layer 260 has a thickness of from about 0.2 mm to about 3 mm. In some embodiments, second bonding layer 260 has a thickness of from about 0.2 mm to about 2 mm. In some embodiments, second bonding layer 260 has a thickness of from 0.2 mm to about 1 mm.
In other embodiments of the disclosure, a negative pressure distribution layer is included in the dressing. With reference to
In device 300, negative pressure distribution layer 370 has length and width dimensions corresponding to the length and width dimensions of absorbent layer 310. In other embodiments, negative pressure distribution layer 370 has dimensions different than absorbent layer 310. With the layers bonded together as shown, when peripheral skin contact layer 330 is affixed to a patient's skin surrounding a wound, negative pressure distribution layer 370, is also situated, along with absorbent layer 310, within an airtight sealed chamber of dressing 300 that is formed by peripheral skin contact layer 330, structural layer 350, second bonding layer 360 and first bonding layer 340, together with cover layer 320 and the patient's skin. Within the chamber, the patient's wound is in fluid communication with absorbent layer 310, negative pressure distribution layer 370 and aperture 228 in cover layer 320.
In some embodiments, negative pressure distribution layer 370 is gas and liquid permeable and particularly moisture vapour permeable and serves to aid access of exudate to a greater area of absorbent layer 310 by distributing negative pressure laterally over dressing 300 and allowing exudate to spread under negative pressure distribution layer 370. Negative pressure distribution layer 370 also serves to even out the negative pressure applied to the wound over the whole dressing. Negative pressure distribution layer 370 preferably distributes exudate and negative pressure over the dressing. In this way, uptake of exudate by absorbent layer 310 is maximised and a more uniform transfer of negative pressure to the wound, or dressing 300, is optimized.
In some embodiments, negative pressure distribution layer 370 is a foam layer such as a polyester foam of the type XD4200AS manufactured by Caligen or another suitable reticulated foam. In other embodiments, negative pressure distribution layer 370 can comprise or be formed from any suitable material, for example, a material which can allow the transport of negative pressures to a wound site and/or which can channel and/or wick wound fluid and/or wound debris away from the wound site. For example, negative pressure distribution layer 370 can comprise or be formed from a material selected from the group consisting of a nonwoven material, a polymer and a combination thereof. In some embodiments, negative pressure distribution layer 370 may be formed from a nonwoven material. The nonwoven material may comprise natural fibers, synthetic fibers, continuous fibers, staple fibers, discontinuous fibers, bicomponent fibers and combinations thereof. In some embodiments, the nonwoven material may comprise polyolefin fibers (e.g., polypropylene, polyethylene), polyester, polyethylene terephthalate (PET), nylon, cotton, and combinations and copolymers thereof. A nonwoven material may be formed from various process known in the art, for example, meltblowing processes, spunbonding processes, spunlaid processes, airlaid processes, wetlaid processes, thermal bonded processes, bonded carded web processes, and combinations thereof. Examples of non-woven materials include, but are not limited to, co-polyester from Libeltex BVBA and HRM or polyolefin fibers in a matrix from Essentra.
In some embodiments, negative pressure distribution layer 370 may be formed from a polymer, for example, a thermoplastic elastomer (TPE), silicone, or a foam. Examples of TPE include, but are not limited to styrene ethylene butylene styrene (SEBS) copolymers or thermoplastic polyurethane (TPU). Negative pressure distribution layer 370 may be formed by combining sheets of TPE or TPU having a thickness between about 0.2 mm and about 2.0 mm. In some embodiments, the sheets of TPE or TPU may be bonded, welded, adhered, or otherwise coupled to one another. For example, in some embodiments, the sheets of TPE or TPU may be welded using radiant heat, radio-frequency welding, or laser welding. Supracor, Inc., Hexacor, Ltd., Hexcel Corp., and Econocorp, Inc. may produce suitable TPE or TPU sheets for the formation of negative pressure distribution layer 370. In some embodiments, negative pressure distribution layer 370 may be formed from a 3D textile, also referred to as a spacer fabric. Suitable 3D textiles may be produced by Heathcoat Fabrics, Ltd., Baltex, and Mueller Textil Group.
In some embodiments, negative pressure distribution layer 370 may be formed from foam. For example, cellular foam, open-cell foam, reticulated foam, or porous tissue collections, may be used to form negative pressure distribution layer 370. In some embodiments, negative pressure distribution layer 370 may be formed of grey foam or Zotefoam. Grey foam may be polyester polyurethane foam having about 60 pores per inch (ppi). Zotefoam may be a closed-cell, cross-linked polyolefin foam. In some non-limiting examples, negative pressure distribution layer 370 may comprise or consist essentially of be reticulated polyurethane foam such as found in GRANUFOAM™ dressing or V.A.C. VERAFLO™ dressing, both available from Kinetic Concepts, Inc. of San Antonio, Tex.
In some embodiments, negative pressure distribution layer 370 may comprise or consist essentially of foam that is mechanically or chemically compressed to increase the density of the foam at ambient pressure. Foam that is mechanically or chemically compressed may be referred to as compressed foam or felted foam. Compressed foam may be characterized by a firmness factor, which may be defined as a ratio of the density of foam in a compressed state to the density of the same foam in an uncompressed state. For example, a firmness factor of 5 may refer to compressed foam having a density that is five times greater than a density of the same foam in an uncompressed state. Mechanically or chemically compressing foam may also reduce a thickness of the foam at ambient pressure when compared to the same foam that has not been compressed. Reducing a thickness of foam by mechanical or chemical compression may increase a density of the foam, which may increase the firmness factor of the foam. Increasing the firmness factor of foam may increase a stiffness of the foam in a direction that is parallel to a thickness of the foam. For example, increasing a firmness factor of negative pressure distribution layer 370 may increase a stiffness of negative pressure distribution layer 370 in a direction that is parallel to the thickness of the layer. In some embodiments, negative pressure distribution layer 370 may have a density of about 0.03 grams per centimeter3 (g/cm3) in its uncompressed state. In its compressed state, negative pressure distribution layer 370 may have a firmness factor (FF) of about 5, and the density may be about 0.15 g/cm3.
Generally, if compressed foam is subjected to negative pressure, the compressed foam exhibits less deformation or compression set than a similar uncompressed foam. If negative pressure distribution layer 370 is formed of compressed foam, the thickness of negative pressure distribution layer 370 may deform less than if negative pressure distribution layer 370 is formed of a comparable uncompressed foam. The decrease in deformation may be caused by the increased stiffness as reflected by the firmness factor. If subjected to the stress of negative pressure, negative pressure distribution layer 370 formed of compressed foam may flatten less than negative pressure distribution layer 370 that is formed from uncompressed foam. Consequently, when negative pressure is applied to negative pressure distribution layer 370, the stiffness of negative pressure distribution layer 370 in the direction parallel to the thickness of negative pressure distribution layer 370 can allow negative pressure distribution layer 370 to be more compliant or compressible in other directions, e.g., a direction parallel to the wound surface. The pore size of a foam material may vary according to needs of negative pressure distribution layer 370 and the amount of compression of the foam. For example, in some embodiments, uncompressed foam may have pore sizes in a range of about 400 microns to about 600 microns. If the same foam is compressed, the pore sizes may be smaller than when the foam is in its uncompressed state.
In some embodiments, negative pressure distribution layer 370 may be formed from a polymer via injection molding or extrusion techniques.
In some embodiments, negative pressure distribution layer 370 may be a single layer, for example as shown in
In another aspect of the present disclosure, the dressing described in previous embodiments contains a connector to be used for fluid communication through the layers. In one embodiment, a connector is coupled to the cover layer such that the connector allows fluid communication with the sealed space beneath the cover layer. The connecter is affixed to the aperture in the cover layer. The connector can be connected to a device used to produce a vacuum (such as a vacuum pump) in order to produce a reduced pressure under the cover layer.
In some embodiments, the connector can be constructed from semi-rigid material such as polyurethane film or polyvinyl chloride. Non-limiting examples of rigid or semi-rigid materials include silicone, acrylics, cyanoacrylate, rubbers, foams, cellulose, polyurethanes, polyethylenes, polyvinyl chlorides, ethylenevinyl acetates, polypropylenes, polytetrafluorethylenes, and polyisobutylenes. In some embodiments, the connector may contain additional textile material layers in order to slow down or modulate exudate draining. In some embodiments, the connector may optionally contain a change disk indicator to alert the user when it is time to change the dressing.
In other embodiments, dressings disclosed herein can be configured for connection to a vacuum pump or other negative pressure source, for example, using flexible tubes. In this way, a fluid communication pathway is provided from the wound, through one or more layers of absorbent material disposed in the dressing, to the negative pressure source. The fluid communication pathway may extend through an aperture in the cover layer to the interior lumen of a tube, optionally via the interior lumen or conduit of a flexible connector. A typical flexible connector is elongate with an interior lumen or conduit that runs parallel to the longitudinal axis of the flexible connector, wherein the flexible connector is attachable to the opening in the cover layer of the dressing in an orientation such that the longitudinal axis of the flexible connector is substantially parallel to the plane of the cover layer. The flexible member may comprise a head portion for securement to the cover layer via adhesive or other means. Typically, the fluid communication pathway extends from the interior lumen or conduit of the flexible connector through the opening in the cover layer in a direction substantially perpendicular to the longitudinal axis of the flexible connector. Once secured, a fluid-tight seal may be formed between the flexible connector and the cover layer.
In use, the dressing embodiments described herein may be secured to the skin surrounding a wound and to a conduit that is configured for connection to a source of negative pressure by a connector located at the distal end of the conduit. Negative pressure is applied to the wound by the application of negative pressure through a pathway for fluid leading from the wound, through the absorbent layer, the aperture in the cover layer and to the distal end of the conduit. Optional fenestrations that may be present in the absorbent layer, assist with the absorbance of exudate and that application of negative pressure.
In another aspect of this present disclosure, the dressing according to any embodiment disclosed herein can include a mobile vacuum pump affixed the dressing in fluid communication with the aperture defined in the cover layer of the dressing. In some embodiments, the dressing includes an “on board” vacuum system that includes a pump that is sufficiently small to be attached directly to the dressing. Such a configuration enables the manufacture and use of disposable dressing/pump combinations.
While a number of discrete embodiments have been described, aspects of each embodiment may not be specific to only that embodiment and it is specifically contemplated that features of embodiments may be combined with features of other embodiments. As will be appreciated from the descriptions herein and the associated Figures, a wide variety of aspects and embodiments are contemplated by the present disclosure, examples of which include, without limitation, the aspects and embodiments listed below:
A unitary negative pressure wound dressing construct that includes: (i) an absorbent layer having a first surface for contacting a wound and a second surface opposite the first surface, the absorbent layer comprising a gelling absorbent material, wherein the absorbent layer has a perimeter border, (ii) a cover layer having a first surface facing the absorbent layer and a second surface opposite the first surface, wherein the cover layer has a perimeter border having dimensions greater than dimensions of the absorbent layer perimeter such that the perimeter border of the cover layer extends beyond the perimeter border of the absorbent layer, and (iii) a peripheral adhesive skin contact layer attached to the first surface of the absorbent layer adjacent the perimeter border of the absorbent layer, wherein the peripheral adhesive skin contact layer defines a window through which the absorbent layer is able to contact the wound, and wherein the peripheral adhesive skin contact layer comprises a hydrocolloid adhesive, wherein the peripheral adhesive skin contact layer has a perimeter border having dimensions greater than the dimensions of the absorbent layer perimeter such that the perimeter border of the peripheral adhesive skin contact layer extends beyond the perimeter border of the absorbent layer, wherein the perimeter border of the cover layer and the perimeter border of the peripheral skin contact layer are bonded together to form a seal, wherein the peripheral adhesive skin contact layer is operable to adhere to skin surrounding a wound, and wherein the cover layer defines an aperture configured for connection to a source of negative pressure.
A dressing in accordance with any other embodiment disclosed herein, wherein the dimensions of the perimeter border of the absorbent layer are greater than dimensions of a wound to be covered by the dressing.
A dressing in accordance with any other embodiment disclosed herein, wherein the cover layer is water impermeable and air and vapour permeable.
A dressing in accordance with any other embodiment disclosed herein, wherein the peripheral adhesive skin contact layer and the cover layer are operable to form an air-tight seal between the absorbent layer and an external environment of the dressing when the dressing is applied over a wound and a source of negative pressure is sealingly connected to the aperture.
A dressing in accordance with any other embodiment disclosed herein, wherein the peripheral adhesive skin contact layer has a thickness of from about 0.1 mm to about 5 mm.
A dressing in accordance with any other embodiment disclosed herein, wherein the peripheral adhesive skin contact layer has a width of from about 2 cm to about 6 cm.
A dressing in accordance with any other embodiment disclosed herein, further comprising a first bonding layer positioned between the absorbent layer and the cover layer.
A dressing in accordance with any other embodiment disclosed herein, wherein the first bonding layer comprises a layer of hydrocolloid adhesive.
A dressing in accordance with any other embodiment disclosed herein, wherein the first bonding layer has a thickness of from about 0.2 mm to about 2 mm.
A dressing in accordance with any other embodiment disclosed herein, further comprising a structural layer corresponding to the peripheral adhesive skin contact layer and having a first surface bonded to the peripheral adhesive skin contact layer, and a second bonding layer corresponding to the peripheral adhesive skin contact layer and positioned in contact with a second surface of the structural layer that is opposite the first surface of the structural layer, wherein the structural layer is positioned between, and sealingly bonded to, the peripheral adhesive skin contact layer and the second bonding layer, and wherein the second bonding layer is sealingly bonded to a continuous portion of the first surface of the absorbent layer that is adjacent the full perimeter border of the absorbent layer.
A dressing in accordance with any other embodiment disclosed herein, wherein the peripheral adhesive skin contact layer, the second bonding layer and the cover layer are operable to form an air-tight seal between the absorbent layer and an external environment of the dressing when the dressing is applied over a wound and a source of negative pressure is sealingly connected to the aperture.
A dressing in accordance with any other embodiment disclosed herein, wherein the structural layer comprises a polyurethane film.
A dressing in accordance with any other embodiment disclosed herein, wherein the second bonding layer has a thickness of from about 0.2 mm to about 2 mm.
A dressing in accordance with any other embodiment disclosed herein, further comprising a first bonding layer positioned between the absorbent layer and the cover layer, a structural layer corresponding to the peripheral adhesive skin contact layer and having a first surface bonded to the adhesive skin contact layer, and a second bonding layer corresponding to the peripheral adhesive skin contact layer and positioned in contact with a second surface of the structural layer that is opposite the first surface of the structural layer, wherein the structural layer is positioned between, and sealingly bonded to, the peripheral adhesive skin contact layer and the second bonding layer, and wherein the second bonding layer is sealingly bonded to a continuous portion of the first surface of the absorbent layer that is adjacent the full perimeter border of the absorbent layer.
A dressing in accordance with any other embodiment disclosed herein, wherein the gelling absorbent material comprises a gel-forming fiber or filament.
A dressing in accordance with any other embodiment disclosed herein, wherein the gel-forming fiber or filament comprising chemically-modified cellulose, alginate, carboxymethyl cellulose, or combinations thereof.
A dressing in accordance with any other embodiment disclosed herein, wherein the absorbent layer comprises stitches.
A dressing in accordance with any other embodiment disclosed herein, wherein the absorbent layer further comprises an antimicrobial agent.
A dressing in accordance with any other embodiment disclosed herein, wherein the cover layer comprises a member selected from the group consisting of a polyurethane (PU), a polyvinyl chloride (PVC), a silicone elastomer, a fluoropolymer, and combinations thereof.
A dressing in accordance with any other embodiment disclosed herein, further comprising a source of negative pressure sealingly connected to the aperture and in fluid communication with the absorbent layer.
A dressing in accordance with any other embodiment disclosed herein, wherein the source of negative pressure comprises a pump connected to the aperture with a conduit.
A dressing in accordance with any other embodiment disclosed herein, further comprising a negative pressure distribution layer positioned between the absorbent layer and the cover layer.
A dressing in accordance with any other embodiment disclosed herein, wherein the negative pressure distribution layer comprises an open cell foam layer.
A dressing in accordance with any other embodiment disclosed herein, wherein the open cell foam layer is hydrophobic.
A dressing in accordance with any other embodiment disclosed herein, further comprising a connector attached to the cover layer over the aperture and configured for connection to a conduit to communicate negative pressure from the conduit to the wound through the aperture.
A dressing in accordance with any other embodiment disclosed herein, wherein the connecter comprises polyurethane or polyvinylchloride.
A dressing in accordance with any other embodiment disclosed herein, wherein the connecter comprises a change indicator.
A disposable negative pressure wound therapy device that includes: (i) a disposable pump for generating negative pressure, and (ii) a dressing in accordance with any dressing embodiment disclosed herein for covering and protecting a wound, wherein the cover layer defines an aperture connected to the pump.
A device in accordance with any other embodiment disclosed herein, further comprising: (iii) a conduit defining a lumen that provides fluid communication between the pump and the aperture defined in the cover layer of the dressing, whereby operation of the pump creates negative pressure at the site of a wound when the dressing is affixed over the wound by pressure sealing the peripheral adhesive skin contact layer to skin surrounding the wound.
While embodiments of the present disclosure have been shown and described herein, it is to be understood by those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
| Number | Name | Date | Kind |
|---|---|---|---|
| 10016537 | Menon et al. | Jul 2018 | B2 |
| 10046096 | Askem et al. | Aug 2018 | B2 |
| 10076447 | Barta et al. | Sep 2018 | B2 |
| 10076587 | Locke et al. | Sep 2018 | B2 |
| 10143784 | Walton et al. | Dec 2018 | B2 |
| 10426670 | von Blucher et al. | Oct 2019 | B2 |
| 10426747 | Johnson | Oct 2019 | B2 |
| 10426874 | Chien et al. | Oct 2019 | B2 |
| 10426875 | Blott et al. | Oct 2019 | B2 |
| 10426938 | Locke et al. | Oct 2019 | B2 |
| 10434015 | Taylor et al. | Oct 2019 | B2 |
| 10434142 | Niazi et al. | Oct 2019 | B2 |
| 10434210 | Olson et al. | Oct 2019 | B2 |
| 10434284 | Hanson et al. | Oct 2019 | B2 |
| 10449094 | Donda et al. | Oct 2019 | B2 |
| D866756 | Allen et al. | Nov 2019 | S |
| 10463760 | Karthikeyan et al. | Nov 2019 | B2 |
| 10463773 | Haggstrom et al. | Nov 2019 | B2 |
| 10470933 | Riesinger | Nov 2019 | B2 |
| 10470936 | Wohlgemuth et al. | Nov 2019 | B2 |
| 10471122 | Shi et al. | Nov 2019 | B2 |
| 10471190 | Locke et al. | Nov 2019 | B2 |
| 10478345 | Barta et al. | Nov 2019 | B2 |
| 10478346 | Knutson | Nov 2019 | B2 |
| 10478394 | Yu | Nov 2019 | B2 |
| 10485707 | Sexton | Nov 2019 | B2 |
| 10485891 | Andrews et al. | Nov 2019 | B2 |
| 10485892 | Hands et al. | Nov 2019 | B2 |
| 10485906 | Freedman et al. | Nov 2019 | B2 |
| 10486135 | Yang et al. | Nov 2019 | B2 |
| 10492956 | Zamierowski | Dec 2019 | B2 |
| 10493178 | Marchant et al. | Dec 2019 | B2 |
| 10493184 | Collinson et al. | Dec 2019 | B2 |
| 10493185 | Stokes et al. | Dec 2019 | B2 |
| 10500099 | Hung et al. | Dec 2019 | B2 |
| 10500103 | Croizat et al. | Dec 2019 | B2 |
| 10500104 | Sookraj | Dec 2019 | B2 |
| 10500173 | Yang et al. | Dec 2019 | B2 |
| 10500235 | Wardell | Dec 2019 | B2 |
| 10500300 | Dybe et al. | Dec 2019 | B2 |
| 10500301 | Laurensou | Dec 2019 | B2 |
| 10500302 | Holm et al. | Dec 2019 | B2 |
| 10501487 | Andrews et al. | Dec 2019 | B2 |
| 10506928 | Locke et al. | Dec 2019 | B2 |
| 10507141 | Allen et al. | Dec 2019 | B2 |
| 10507259 | Cree et al. | Dec 2019 | B2 |
| 10512707 | Whalen, III et al. | Dec 2019 | B2 |
| 10525170 | Havenstrite et al. | Jan 2020 | B2 |
| 10532137 | Pratt et al. | Jan 2020 | B2 |
| 10532194 | Locke et al. | Jan 2020 | B2 |
| 10537657 | Phillips et al. | Jan 2020 | B2 |
| 10542936 | Goldberg et al. | Jan 2020 | B2 |
| 10543133 | Shaw et al. | Jan 2020 | B2 |
| 10543293 | Suschek | Jan 2020 | B2 |
| 10548777 | Locke et al. | Feb 2020 | B2 |
| 10549008 | Yoo | Feb 2020 | B2 |
| 10549016 | Bushko et al. | Feb 2020 | B2 |
| 10549017 | Hsiao et al. | Feb 2020 | B2 |
| 10555838 | Wu et al. | Feb 2020 | B2 |
| 10555839 | Hartwell | Feb 2020 | B2 |
| 10556044 | Robinson et al. | Feb 2020 | B2 |
| 10561533 | Hoggarth et al. | Feb 2020 | B2 |
| 10561536 | Holm et al. | Feb 2020 | B2 |
| 10568767 | Addison et al. | Feb 2020 | B2 |
| 10568768 | Long et al. | Feb 2020 | B2 |
| 10568770 | Robinson et al. | Feb 2020 | B2 |
| 10568771 | MacDonald et al. | Feb 2020 | B2 |
| 10568773 | Tuck et al. | Feb 2020 | B2 |
| 10568983 | Gerdes et al. | Feb 2020 | B2 |
| 10575991 | Dunn | Mar 2020 | B2 |
| 10575992 | Sarangapani et al. | Mar 2020 | B2 |
| 10576037 | Harrell | Mar 2020 | B2 |
| 10576189 | Locke et al. | Mar 2020 | B2 |
| 10583042 | Sarangapani et al. | Mar 2020 | B2 |
| 10583228 | Shuler et al. | Mar 2020 | B2 |
| 10589007 | Coulthard et al. | Mar 2020 | B2 |
| 10590184 | Kuo | Mar 2020 | B2 |
| 10610414 | Hartwell et al. | Apr 2020 | B2 |
| 10610415 | Griffey et al. | Apr 2020 | B2 |
| 10610623 | Robinson et al. | Apr 2020 | B2 |
| 10617569 | Bonn | Apr 2020 | B2 |
| 10617608 | Shin et al. | Apr 2020 | B2 |
| 10617769 | Huang | Apr 2020 | B2 |
| 10617784 | Yu et al. | Apr 2020 | B2 |
| 10617786 | Kluge et al. | Apr 2020 | B2 |
| 10618266 | Wright et al. | Apr 2020 | B2 |
| 10624984 | Courage et al. | Apr 2020 | B2 |
| 10625002 | Locke et al. | Apr 2020 | B2 |
| 10632019 | Vitaris | Apr 2020 | B2 |
| 10632224 | Hardy et al. | Apr 2020 | B2 |
| 10639206 | Hu et al. | May 2020 | B2 |
| 10639350 | Arber et al. | May 2020 | B2 |
| 10639404 | Lichtenstein | May 2020 | B2 |
| 10646614 | Grinstaff et al. | May 2020 | B2 |
| 10653562 | Robinson et al. | May 2020 | B2 |
| 10653782 | Ameer et al. | May 2020 | B2 |
| 10653810 | Datt et al. | May 2020 | B2 |
| 10653821 | Nichols | May 2020 | B2 |
| 10653823 | Bharti et al. | May 2020 | B2 |
| 10660799 | Wu et al. | May 2020 | B2 |
| 10660851 | Millis et al. | May 2020 | B2 |
| 10660992 | Canner et al. | May 2020 | B2 |
| 10660994 | Askem et al. | May 2020 | B2 |
| 10667955 | Allen et al. | Jun 2020 | B2 |
| 10667956 | Van Holten et al. | Jun 2020 | B2 |
| 10682257 | Lu | Jun 2020 | B2 |
| 10682258 | Manwaring et al. | Jun 2020 | B2 |
| 10682259 | Hunt et al. | Jun 2020 | B2 |
| 10682318 | Twomey et al. | Jun 2020 | B2 |
| 10682386 | Ellis-Behnke et al. | Jun 2020 | B2 |
| 10682446 | Askem et al. | Jun 2020 | B2 |
| 10687983 | Dahlberg et al. | Jun 2020 | B2 |
| 10687985 | Lee et al. | Jun 2020 | B2 |
| 10688215 | Munro et al. | Jun 2020 | B2 |
| 10688217 | Hanson et al. | Jun 2020 | B2 |
| RE48117 | Albert et al. | Jul 2020 | E |
| 10702419 | Locke et al. | Jul 2020 | B2 |
| 10702420 | Hammond et al. | Jul 2020 | B2 |
| 10703942 | Tunius | Jul 2020 | B2 |
| 10709760 | Gronberg et al. | Jul 2020 | B2 |
| 10709807 | Kshirsagar | Jul 2020 | B2 |
| 10709883 | Spector | Jul 2020 | B2 |
| 10716711 | Locke et al. | Jul 2020 | B2 |
| 10716874 | Koyama et al. | Jul 2020 | B2 |
| 10729589 | Dorian et al. | Aug 2020 | B2 |
| 10729590 | Simmons et al. | Aug 2020 | B2 |
| 10729826 | Lin | Aug 2020 | B2 |
| 10736787 | Hannigan et al. | Aug 2020 | B2 |
| 10736788 | Locke et al. | Aug 2020 | B2 |
| 10736985 | Odermatt et al. | Aug 2020 | B2 |
| 10737003 | Fujisaki | Aug 2020 | B2 |
| 10743900 | Ingram et al. | Aug 2020 | B2 |
| 10744040 | Kazala, Jr. et al. | Aug 2020 | B2 |
| 10744041 | Hartwell | Aug 2020 | B2 |
| 10744225 | Lindgren et al. | Aug 2020 | B2 |
| 10744237 | Guidi et al. | Aug 2020 | B2 |
| 10744238 | Guidi et al. | Aug 2020 | B2 |
| 10744239 | Armstrong et al. | Aug 2020 | B2 |
| 10744240 | Simmons et al. | Aug 2020 | B2 |
| 10751212 | Raza et al. | Aug 2020 | B2 |
| 10751442 | Bonnefin et al. | Aug 2020 | B2 |
| 10751452 | Topaz | Aug 2020 | B2 |
| 10758423 | Pigg et al. | Sep 2020 | B2 |
| 10758424 | Blott et al. | Sep 2020 | B2 |
| 10758425 | Blott et al. | Sep 2020 | B2 |
| 10758426 | Eddy | Sep 2020 | B2 |
| 10758651 | Blott et al. | Sep 2020 | B2 |
| 10765561 | Lattimore et al. | Sep 2020 | B2 |
| 10765783 | Locke et al. | Sep 2020 | B2 |
| 10772767 | Bjork et al. | Sep 2020 | B2 |
| 10772999 | Svensby | Sep 2020 | B2 |
| 10779993 | Bishop et al. | Sep 2020 | B2 |
| 10780194 | Flach et al. | Sep 2020 | B2 |
| 10780201 | Lin | Sep 2020 | B2 |
| 10780202 | Askem et al. | Sep 2020 | B2 |
| 10780203 | Coulthard et al. | Sep 2020 | B2 |
| 10782238 | Hicks et al. | Sep 2020 | B2 |
| 10792191 | Robinson et al. | Oct 2020 | B2 |
| 10792192 | Tout et al. | Oct 2020 | B2 |
| 10792337 | Leung et al. | Oct 2020 | B2 |
| 10792404 | Hu et al. | Oct 2020 | B2 |
| 10792482 | Randolph et al. | Oct 2020 | B2 |
| 10800905 | Delli-Santi et al. | Oct 2020 | B2 |
| 10806819 | Shuler | Oct 2020 | B2 |
| 20060155260 | Blott et al. | Jul 2006 | A1 |
| 20060172000 | Cullen et al. | Aug 2006 | A1 |
| 20070185426 | Ambrosio et al. | Aug 2007 | A1 |
| 20070219512 | Heaton et al. | Sep 2007 | A1 |
| 20070239078 | Jaeb | Oct 2007 | A1 |
| 20090234307 | Vitaris | Sep 2009 | A1 |
| 20090259203 | Hu et al. | Oct 2009 | A1 |
| 20090293887 | Wilkes et al. | Dec 2009 | A1 |
| 20090299303 | Seegert | Dec 2009 | A1 |
| 20100015208 | Kershaw et al. | Jan 2010 | A1 |
| 20100030178 | MacMeccan et al. | Feb 2010 | A1 |
| 20100125233 | Edward S. et al. | May 2010 | A1 |
| 20100125258 | Coulthard et al. | May 2010 | A1 |
| 20100137775 | Hu et al. | Jun 2010 | A1 |
| 20100185163 | Heagle | Jul 2010 | A1 |
| 20100298790 | Guidi et al. | Nov 2010 | A1 |
| 20110015595 | Robinson et al. | Jan 2011 | A1 |
| 20110028918 | Hartwell | Feb 2011 | A1 |
| 20110112457 | Holm et al. | May 2011 | A1 |
| 20110178451 | Robinson et al. | Jul 2011 | A1 |
| 20110208145 | Zhang | Aug 2011 | A1 |
| 20110224593 | Tunius | Sep 2011 | A1 |
| 20110224630 | Simmons et al. | Sep 2011 | A1 |
| 20110230849 | Coulthard et al. | Sep 2011 | A1 |
| 20110251566 | Zimnitsky et al. | Oct 2011 | A1 |
| 20110257572 | Locke et al. | Oct 2011 | A1 |
| 20110257573 | Hong et al. | Oct 2011 | A1 |
| 20110275972 | Rosenberg | Nov 2011 | A1 |
| 20120071845 | Hu et al. | Mar 2012 | A1 |
| 20120130332 | Cotton | May 2012 | A1 |
| 20120136325 | Allen et al. | May 2012 | A1 |
| 20120209226 | Simmons et al. | Aug 2012 | A1 |
| 20130053795 | Coulthard et al. | Feb 2013 | A1 |
| 20130123728 | Pratt et al. | May 2013 | A1 |
| 20130226063 | Taylor et al. | Aug 2013 | A1 |
| 20140005618 | Locke et al. | Jan 2014 | A1 |
| 20140074053 | Locke et al. | Mar 2014 | A1 |
| 20140188060 | Robinson et al. | Jul 2014 | A1 |
| 20140194838 | Wibaux et al. | Jul 2014 | A1 |
| 20140200532 | Robinson et al. | Jul 2014 | A1 |
| 20140236112 | Von Wolff | Aug 2014 | A1 |
| 20140256925 | Catchmark et al. | Sep 2014 | A1 |
| 20140276499 | Locke et al. | Sep 2014 | A1 |
| 20140296804 | Hicks et al. | Oct 2014 | A1 |
| 20140308338 | Nierle et al. | Oct 2014 | A1 |
| 20140309574 | Cotton | Oct 2014 | A1 |
| 20150018433 | Leipzig et al. | Jan 2015 | A1 |
| 20150057624 | Simmons et al. | Feb 2015 | A1 |
| 20150071985 | Walker et al. | Mar 2015 | A1 |
| 20150079152 | Wuollet et al. | Mar 2015 | A1 |
| 20150094674 | Pratt et al. | Apr 2015 | A1 |
| 20150104486 | Bonnefin et al. | Apr 2015 | A1 |
| 20150112311 | Hammond et al. | Apr 2015 | A1 |
| 20150119831 | Robinson et al. | Apr 2015 | A1 |
| 20150119834 | Locke et al. | Apr 2015 | A1 |
| 20150141941 | Allen et al. | May 2015 | A1 |
| 20150148785 | Kleiner | May 2015 | A1 |
| 20150174304 | Askem et al. | Jun 2015 | A1 |
| 20150231858 | van Neer | Aug 2015 | A1 |
| 20150245949 | Locke et al. | Sep 2015 | A1 |
| 20150246164 | Heaton et al. | Sep 2015 | A1 |
| 20150250979 | Loske | Sep 2015 | A1 |
| 20150265741 | Duncan et al. | Sep 2015 | A1 |
| 20150265743 | Hanson et al. | Sep 2015 | A1 |
| 20150320901 | Chandrashekhar-Bhat et al. | Nov 2015 | A1 |
| 20160008293 | Shi et al. | Jan 2016 | A1 |
| 20160038626 | Locke et al. | Feb 2016 | A1 |
| 20160051724 | Sahin et al. | Feb 2016 | A1 |
| 20160067107 | Cotton | Mar 2016 | A1 |
| 20160100987 | Hartwell et al. | Apr 2016 | A1 |
| 20160106878 | Yang et al. | Apr 2016 | A1 |
| 20160106892 | Hartwell | Apr 2016 | A1 |
| 20160166422 | Karim et al. | Jun 2016 | A1 |
| 20160193244 | Ota et al. | Jul 2016 | A1 |
| 20160222548 | Agboh | Aug 2016 | A1 |
| 20160271178 | Hauser et al. | Sep 2016 | A1 |
| 20160287743 | Andrews | Oct 2016 | A1 |
| 20160339158 | Collinson et al. | Nov 2016 | A1 |
| 20160374847 | Lachenbruch et al. | Dec 2016 | A1 |
| 20170014275 | Schneider | Jan 2017 | A1 |
| 20170049111 | Patton et al. | Feb 2017 | A1 |
| 20170072669 | Sekido et al. | Mar 2017 | A1 |
| 20170128269 | Coulthard et al. | May 2017 | A1 |
| 20170189237 | Locke et al. | Jul 2017 | A1 |
| 20170189575 | Lee et al. | Jul 2017 | A1 |
| 20170209615 | Tornero Garcia et al. | Jul 2017 | A1 |
| 20170232161 | Fewkes et al. | Aug 2017 | A1 |
| 20170258956 | Flach et al. | Sep 2017 | A1 |
| 20170367895 | Holm et al. | Dec 2017 | A1 |
| 20170368239 | Askem et al. | Dec 2017 | A1 |
| 20180008742 | Hoggarth et al. | Jan 2018 | A1 |
| 20180014974 | Hoggarth et al. | Jan 2018 | A1 |
| 20180023217 | Patton et al. | Jan 2018 | A1 |
| 20180030321 | Tunius | Feb 2018 | A1 |
| 20180042789 | Bradford et al. | Feb 2018 | A1 |
| 20180078423 | Magin et al. | Mar 2018 | A1 |
| 20180086903 | Zhang et al. | Mar 2018 | A1 |
| 20180118809 | Mearns Spragg | May 2018 | A1 |
| 20180133066 | Ahsani et al. | May 2018 | A1 |
| 20180140467 | Hunt | May 2018 | A1 |
| 20180140822 | Robinson et al. | May 2018 | A1 |
| 20180200414 | Askem et al. | Jul 2018 | A1 |
| 20180221531 | Bender et al. | Aug 2018 | A1 |
| 20180236124 | Young et al. | Aug 2018 | A1 |
| 20180243463 | Chatterjee et al. | Aug 2018 | A1 |
| 20180243464 | Hwang et al. | Aug 2018 | A1 |
| 20180244857 | Lee et al. | Aug 2018 | A1 |
| 20180272052 | Locke et al. | Sep 2018 | A1 |
| 20180296397 | Askem et al. | Oct 2018 | A1 |
| 20180303873 | Been et al. | Oct 2018 | A1 |
| 20180311419 | Locke et al. | Nov 2018 | A1 |
| 20180333522 | Pratt et al. | Nov 2018 | A1 |
| 20180344533 | Rovaniemi | Dec 2018 | A1 |
| 20180353334 | Locke et al. | Dec 2018 | A1 |
| 20180353337 | Locke | Dec 2018 | A1 |
| 20180353339 | Locke et al. | Dec 2018 | A1 |
| 20180353340 | Robinson et al. | Dec 2018 | A1 |
| 20180353344 | Locke et al. | Dec 2018 | A1 |
| 20180353662 | Locke et al. | Dec 2018 | A1 |
| 20180353663 | Locke et al. | Dec 2018 | A1 |
| 20180360667 | Droche | Dec 2018 | A1 |
| 20190000677 | Munro | Jan 2019 | A1 |
| 20190015258 | Gowans et al. | Jan 2019 | A1 |
| 20190015468 | Yadav et al. | Jan 2019 | A1 |
| 20190030223 | Lin | Jan 2019 | A1 |
| 20190046682 | Choi et al. | Feb 2019 | A1 |
| 20190060127 | Locke et al. | Feb 2019 | A1 |
| 20190083752 | Howell et al. | Mar 2019 | A1 |
| 20190117465 | Osborne et al. | Apr 2019 | A1 |
| 20190117466 | Kazala, Jr. et al. | Apr 2019 | A1 |
| 20190117861 | Locke et al. | Apr 2019 | A1 |
| 20190125590 | Rehbein et al. | May 2019 | A1 |
| 20190133830 | Bishop | May 2019 | A1 |
| 20190151155 | Bonn | May 2019 | A1 |
| 20190151159 | Gowans et al. | May 2019 | A1 |
| 20190151495 | Helary et al. | May 2019 | A1 |
| 20190184052 | Ilan et al. | Jun 2019 | A1 |
| 20190231600 | Locke et al. | Aug 2019 | A1 |
| 20190231602 | Locke et al. | Aug 2019 | A1 |
| 20190231943 | Robinson et al. | Aug 2019 | A1 |
| 20190274889 | Steward et al. | Sep 2019 | A1 |
| 20190282728 | Kellar et al. | Sep 2019 | A1 |
| 20190290799 | Arshi et al. | Sep 2019 | A1 |
| 20190298249 | Bates et al. | Oct 2019 | A1 |
| 20190298577 | Locke et al. | Oct 2019 | A1 |
| 20190298578 | Shulman et al. | Oct 2019 | A1 |
| 20190298579 | Moore et al. | Oct 2019 | A1 |
| 20190298580 | Hall et al. | Oct 2019 | A1 |
| 20190298582 | Addison et al. | Oct 2019 | A1 |
| 20190298881 | Ramjit et al. | Oct 2019 | A1 |
| 20190298882 | Nelson | Oct 2019 | A1 |
| 20190298895 | Selby et al. | Oct 2019 | A1 |
| 20190307611 | Askem et al. | Oct 2019 | A1 |
| 20190307612 | Hartwell et al. | Oct 2019 | A1 |
| 20190307934 | Allen et al. | Oct 2019 | A1 |
| 20190307935 | Simmons et al. | Oct 2019 | A1 |
| 20190314187 | Emslander et al. | Oct 2019 | A1 |
| 20190314209 | Ha et al. | Oct 2019 | A1 |
| 20190314544 | Filho et al. | Oct 2019 | A1 |
| 20190321232 | Jardret et al. | Oct 2019 | A1 |
| 20190321509 | Chakravarthy et al. | Oct 2019 | A1 |
| 20190321526 | Robinson et al. | Oct 2019 | A1 |
| 20190322795 | Kubo et al. | Oct 2019 | A1 |
| 20190328580 | Emslander et al. | Oct 2019 | A1 |
| 20190336343 | Etchells et al. | Nov 2019 | A1 |
| 20190336344 | Locke | Nov 2019 | A1 |
| 20190336345 | Bannwart | Nov 2019 | A1 |
| 20190336346 | Locke et al. | Nov 2019 | A1 |
| 20190336640 | Vismara et al. | Nov 2019 | A1 |
| 20190336641 | Nisbet | Nov 2019 | A1 |
| 20190336643 | Luukko et al. | Nov 2019 | A1 |
| 20190336658 | Heaton et al. | Nov 2019 | A1 |
| 20190336739 | Locke et al. | Nov 2019 | A1 |
| 20190343687 | Locke et al. | Nov 2019 | A1 |
| 20190343889 | Luukko et al. | Nov 2019 | A1 |
| 20190343979 | Kearney et al. | Nov 2019 | A1 |
| 20190343993 | Weston | Nov 2019 | A1 |
| 20190343994 | Greener | Nov 2019 | A1 |
| 20190344242 | Kim et al. | Nov 2019 | A1 |
| 20190350763 | Pratt et al. | Nov 2019 | A1 |
| 20190350764 | Zochowski et al. | Nov 2019 | A1 |
| 20190350765 | Heagle et al. | Nov 2019 | A1 |
| 20190350775 | Biasutti et al. | Nov 2019 | A1 |
| 20190350970 | Saphier et al. | Nov 2019 | A1 |
| 20190351092 | Silver et al. | Nov 2019 | A1 |
| 20190351093 | Stein et al. | Nov 2019 | A1 |
| 20190351094 | Maher et al. | Nov 2019 | A1 |
| 20190351095 | Maher et al. | Nov 2019 | A1 |
| 20190351111 | Locke et al. | Nov 2019 | A1 |
| 20190358088 | Lavocah et al. | Nov 2019 | A1 |
| 20190358361 | McInnes et al. | Nov 2019 | A1 |
| 20190358372 | Askem et al. | Nov 2019 | A1 |
| 20190365948 | Deegan et al. | Dec 2019 | A1 |
| 20190365962 | Lee et al. | Dec 2019 | A1 |
| 20190374408 | Robles et al. | Dec 2019 | A1 |
| 20190374673 | Hoefinghoff et al. | Dec 2019 | A1 |
| 20190380878 | Edwards et al. | Dec 2019 | A1 |
| 20190380881 | Albert et al. | Dec 2019 | A1 |
| 20190380882 | Taylor et al. | Dec 2019 | A1 |
| 20190380883 | MacPhee et al. | Dec 2019 | A1 |
| 20190381222 | Locke et al. | Dec 2019 | A9 |
| 20190388577 | Chandrashekhar-Bhat et al. | Dec 2019 | A1 |
| 20190388579 | MacPhee et al. | Dec 2019 | A1 |
| 20190388589 | MacPhee et al. | Dec 2019 | A1 |
| 20200000640 | Mondal et al. | Jan 2020 | A1 |
| 20200000642 | Waite | Jan 2020 | A1 |
| 20200000643 | Locke | Jan 2020 | A1 |
| 20200000955 | Andrews et al. | Jan 2020 | A1 |
| 20200000956 | Huang et al. | Jan 2020 | A1 |
| 20200000985 | Seddon et al. | Jan 2020 | A1 |
| 20200008981 | Wheldrake | Jan 2020 | A1 |
| 20200009289 | Torabinejad et al. | Jan 2020 | A1 |
| 20200009400 | Ribeiro et al. | Jan 2020 | A1 |
| 20200017650 | Young et al. | Jan 2020 | A1 |
| 20200022844 | Blott et al. | Jan 2020 | A1 |
| 20200023102 | Powell | Jan 2020 | A1 |
| 20200023103 | Joshi et al. | Jan 2020 | A1 |
| 20200023104 | Eriksson et al. | Jan 2020 | A1 |
| 20200023105 | Long et al. | Jan 2020 | A1 |
| 20200023106 | Carroll et al. | Jan 2020 | A1 |
| 20200030153 | Johannison et al. | Jan 2020 | A1 |
| 20200030480 | Choi | Jan 2020 | A1 |
| 20200030499 | Menon et al. | Jan 2020 | A1 |
| 20200038023 | Dunn | Feb 2020 | A1 |
| 20200038249 | Pratt et al. | Feb 2020 | A1 |
| 20200038250 | Edwards et al. | Feb 2020 | A1 |
| 20200038251 | Locke et al. | Feb 2020 | A1 |
| 20200038252 | Spiro | Feb 2020 | A1 |
| 20200038283 | Hall et al. | Feb 2020 | A1 |
| 20200038470 | Datt et al. | Feb 2020 | A1 |
| 20200038544 | Grover et al. | Feb 2020 | A1 |
| 20200038546 | Dizio et al. | Feb 2020 | A1 |
| 20200038639 | Patel et al. | Feb 2020 | A1 |
| 20200046565 | Barta et al. | Feb 2020 | A1 |
| 20200046566 | Carey et al. | Feb 2020 | A1 |
| 20200046567 | Carroll et al. | Feb 2020 | A1 |
| 20200046568 | Sexton | Feb 2020 | A1 |
| 20200046663 | Murdock et al. | Feb 2020 | A1 |
| 20200046876 | Liu | Feb 2020 | A1 |
| 20200046887 | Runquist et al. | Feb 2020 | A1 |
| 20200054491 | Hentrich et al. | Feb 2020 | A1 |
| 20200054781 | Weiser et al. | Feb 2020 | A1 |
| 20200060879 | Edwards et al. | Feb 2020 | A1 |
| 20200061253 | Long et al. | Feb 2020 | A1 |
| 20200061254 | Joshi et al. | Feb 2020 | A1 |
| 20200061379 | Bogie et al. | Feb 2020 | A1 |
| 20200069183 | Rice et al. | Mar 2020 | A1 |
| 20200069476 | Randolph et al. | Mar 2020 | A1 |
| 20200069477 | Holm et al. | Mar 2020 | A1 |
| 20200069478 | Jabbarzadeh et al. | Mar 2020 | A1 |
| 20200069479 | Buan et al. | Mar 2020 | A1 |
| 20200069835 | Hissink et al. | Mar 2020 | A1 |
| 20200069850 | Beadle et al. | Mar 2020 | A1 |
| 20200069851 | Blott et al. | Mar 2020 | A1 |
| 20200069853 | Hall et al. | Mar 2020 | A1 |
| 20200078223 | Locke et al. | Mar 2020 | A1 |
| 20200078224 | Carroll et al. | Mar 2020 | A1 |
| 20200078225 | Grillitsch et al. | Mar 2020 | A1 |
| 20200078305 | Auvinen et al. | Mar 2020 | A1 |
| 20200078330 | Gay | Mar 2020 | A1 |
| 20200078482 | Yoon et al. | Mar 2020 | A1 |
| 20200078499 | Gadde et al. | Mar 2020 | A1 |
| 20200085625 | Bellini et al. | Mar 2020 | A1 |
| 20200085626 | Braga et al. | Mar 2020 | A1 |
| 20200085629 | Locke et al. | Mar 2020 | A1 |
| 20200085630 | Robinson et al. | Mar 2020 | A1 |
| 20200085632 | Locke et al. | Mar 2020 | A1 |
| 20200085991 | Coomber | Mar 2020 | A1 |
| 20200085992 | Locke et al. | Mar 2020 | A1 |
| 20200086014 | Locke et al. | Mar 2020 | A1 |
| 20200086017 | Jardret et al. | Mar 2020 | A1 |
| 20200086049 | Park et al. | Mar 2020 | A1 |
| 20200093646 | Locke et al. | Mar 2020 | A1 |
| 20200093756 | Sabacinski | Mar 2020 | A1 |
| 20200093953 | Kim et al. | Mar 2020 | A1 |
| 20200093954 | Leise, III | Mar 2020 | A1 |
| 20200093970 | Hunt et al. | Mar 2020 | A1 |
| 20200095421 | Kettel | Mar 2020 | A1 |
| 20200095620 | Kellar et al. | Mar 2020 | A1 |
| 20200100945 | Albert et al. | Apr 2020 | A1 |
| 20200101192 | Folwarzny | Apr 2020 | A1 |
| 20200107964 | Locke et al. | Apr 2020 | A1 |
| 20200107965 | Greener | Apr 2020 | A1 |
| 20200107966 | Francis | Apr 2020 | A1 |
| 20200107967 | Holm et al. | Apr 2020 | A1 |
| 20200108169 | Hu et al. | Apr 2020 | A1 |
| 20200113741 | Rehbein et al. | Apr 2020 | A1 |
| 20200114039 | Wang et al. | Apr 2020 | A1 |
| 20200114040 | Waite et al. | Apr 2020 | A1 |
| 20200114049 | Wall | Apr 2020 | A1 |
| 20200121509 | Locke et al. | Apr 2020 | A1 |
| 20200121510 | Hartwell et al. | Apr 2020 | A1 |
| 20200121513 | Townsend et al. | Apr 2020 | A1 |
| 20200121521 | Daniel et al. | Apr 2020 | A1 |
| 20200121833 | Askem et al. | Apr 2020 | A9 |
| 20200129338 | Gardiner et al. | Apr 2020 | A1 |
| 20200129341 | Coulthard et al. | Apr 2020 | A1 |
| 20200129648 | Drury et al. | Apr 2020 | A1 |
| 20200129654 | Bouvier et al. | Apr 2020 | A1 |
| 20200129655 | Gardiner et al. | Apr 2020 | A1 |
| 20200129675 | Robinson et al. | Apr 2020 | A1 |
| 20200138754 | Johnson | May 2020 | A1 |
| 20200139002 | Dudnyk et al. | May 2020 | A1 |
| 20200139023 | Haggstrom et al. | May 2020 | A1 |
| 20200139025 | Robinson et al. | May 2020 | A1 |
| 20200141031 | Kosan et al. | May 2020 | A1 |
| 20200146894 | Long et al. | May 2020 | A1 |
| 20200146896 | Rice et al. | May 2020 | A1 |
| 20200146897 | Locke et al. | May 2020 | A1 |
| 20200146899 | Pratt et al. | May 2020 | A1 |
| 20200155355 | Hill et al. | May 2020 | A1 |
| 20200155358 | Wheldrake | May 2020 | A1 |
| 20200155359 | Carroll et al. | May 2020 | A1 |
| 20200155361 | Pigg et al. | May 2020 | A1 |
| 20200155379 | Shaw et al. | May 2020 | A1 |
| 20200163802 | Hunt et al. | May 2020 | A1 |
| 20200163803 | Pigg et al. | May 2020 | A1 |
| 20200164112 | Kato et al. | May 2020 | A1 |
| 20200164120 | Jaecklein et al. | May 2020 | A1 |
| 20200170841 | Waite et al. | Jun 2020 | A1 |
| 20200170842 | Locke | Jun 2020 | A1 |
| 20200170843 | Collinson et al. | Jun 2020 | A1 |
| 20200171197 | Hubbell et al. | Jun 2020 | A1 |
| 20200179300 | Urban et al. | Jun 2020 | A1 |
| 20200179558 | Munro et al. | Jun 2020 | A1 |
| 20200179673 | Wan | Jun 2020 | A1 |
| 20200188179 | Bugedo-Albizuri et al. | Jun 2020 | A1 |
| 20200188180 | Akbari et al. | Jun 2020 | A1 |
| 20200188182 | Sanders et al. | Jun 2020 | A1 |
| 20200188183 | Hamerslagh et al. | Jun 2020 | A1 |
| 20200188550 | Dagger et al. | Jun 2020 | A1 |
| 20200188564 | Dunn | Jun 2020 | A1 |
| 20200190310 | Meyer | Jun 2020 | A1 |
| 20200197227 | Locke et al. | Jun 2020 | A1 |
| 20200197228 | Hartwell | Jun 2020 | A1 |
| 20200197559 | Bourdillon et al. | Jun 2020 | A1 |
| 20200197580 | Kilpadi et al. | Jun 2020 | A1 |
| 20200206035 | Kantor et al. | Jul 2020 | A1 |
| 20200206036 | Robinson et al. | Jul 2020 | A1 |
| 20200214637 | Brownhill et al. | Jul 2020 | A1 |
| 20200214897 | Long et al. | Jul 2020 | A1 |
| 20200214898 | Waite et al. | Jul 2020 | A1 |
| 20200214899 | Locke et al. | Jul 2020 | A1 |
| 20200215220 | Schomburg et al. | Jul 2020 | A1 |
| 20200215226 | Kitagawa et al. | Jul 2020 | A1 |
| 20200222469 | Cotton | Jul 2020 | A1 |
| 20200229983 | Robinson et al. | Jul 2020 | A1 |
| 20200230283 | Yang et al. | Jul 2020 | A1 |
| 20200237562 | Rice et al. | Jul 2020 | A1 |
| 20200237564 | Hammond et al. | Jul 2020 | A1 |
| 20200237816 | Lait | Jul 2020 | A1 |
| 20200246190 | Luckemeyer et al. | Aug 2020 | A1 |
| 20200246191 | Lu et al. | Aug 2020 | A1 |
| 20200246194 | Gonzalez et al. | Aug 2020 | A1 |
| 20200246195 | Robinson et al. | Aug 2020 | A1 |
| 20200253785 | Bernet et al. | Aug 2020 | A1 |
| 20200253786 | Harrison et al. | Aug 2020 | A1 |
| 20200253788 | Rehbein et al. | Aug 2020 | A1 |
| 20200254139 | Phillips et al. | Aug 2020 | A1 |
| 20200261275 | Manwaring et al. | Aug 2020 | A1 |
| 20200261276 | Lujan Hernandez et al. | Aug 2020 | A1 |
| 20200268560 | Harrison et al. | Aug 2020 | A1 |
| 20200268561 | Locke et al. | Aug 2020 | A1 |
| 20200269028 | Hegg | Aug 2020 | A1 |
| 20200270484 | Lipscomb et al. | Aug 2020 | A1 |
| 20200276055 | Randolph et al. | Sep 2020 | A1 |
| 20200276058 | Locke et al. | Sep 2020 | A1 |
| 20200277450 | Silverstein et al. | Sep 2020 | A1 |
| 20200281519 | Gowans et al. | Sep 2020 | A1 |
| 20200281529 | Grubb et al. | Sep 2020 | A1 |
| 20200281678 | Long et al. | Sep 2020 | A1 |
| 20200281775 | Kushnir et al. | Sep 2020 | A1 |
| 20200282100 | Gil et al. | Sep 2020 | A1 |
| 20200282114 | Long et al. | Sep 2020 | A1 |
| 20200282115 | Gardner et al. | Sep 2020 | A1 |
| 20200289326 | Nielsen et al. | Sep 2020 | A1 |
| 20200289327 | Hansen et al. | Sep 2020 | A1 |
| 20200289328 | Luckemeyer et al. | Sep 2020 | A1 |
| 20200289346 | Hansen et al. | Sep 2020 | A1 |
| 20200289347 | Gowans et al. | Sep 2020 | A1 |
| 20200289701 | Hall et al. | Sep 2020 | A1 |
| 20200289712 | Jiang et al. | Sep 2020 | A1 |
| 20200289723 | Gregory et al. | Sep 2020 | A1 |
| 20200289726 | Locke et al. | Sep 2020 | A1 |
| 20200289727 | Locke | Sep 2020 | A1 |
| 20200289806 | Locke et al. | Sep 2020 | A1 |
| 20200297541 | Hartwell et al. | Sep 2020 | A1 |
| 20200297543 | Rodzewicz et al. | Sep 2020 | A1 |
| 20200297544 | Moine et al. | Sep 2020 | A1 |
| 20200297892 | Silcock | Sep 2020 | A1 |
| 20200297893 | Ericson | Sep 2020 | A1 |
| 20200297894 | Koyama et al. | Sep 2020 | A1 |
| 20200299865 | Bonnefin et al. | Sep 2020 | A1 |
| 20200306089 | Delury et al. | Oct 2020 | A1 |
| 20200306091 | Lee et al. | Oct 2020 | A1 |
| 20200306092 | Rehbein et al. | Oct 2020 | A1 |
| 20200306094 | Kushnir et al. | Oct 2020 | A1 |
| 20200306426 | Rice et al. | Oct 2020 | A1 |
| 20200306428 | Ingram et al. | Oct 2020 | A1 |
| 20200306430 | Rehbein et al. | Oct 2020 | A1 |
| 20200315853 | Waite | Oct 2020 | A1 |
| 20200315854 | Simmons et al. | Oct 2020 | A1 |
| 20200315894 | Churilla et al. | Oct 2020 | A1 |
| 20200316271 | Lin | Oct 2020 | A1 |
| 20200316272 | Simpson | Oct 2020 | A1 |
| 20200316273 | Hegg | Oct 2020 | A1 |
| 20200323692 | Locke et al. | Oct 2020 | A1 |
| 20200324015 | Kettel et al. | Oct 2020 | A1 |
| 20200330283 | Locke et al. | Oct 2020 | A1 |
| 20200330284 | Locke et al. | Oct 2020 | A1 |
| 20200330285 | Rehbein et al. | Oct 2020 | A1 |
| 20200330658 | Fujisaki | Oct 2020 | A1 |
| 20200330660 | Patel et al. | Oct 2020 | A1 |
| 20200337719 | Ingram et al. | Oct 2020 | A1 |
| 20200337904 | Waite | Oct 2020 | A1 |
| 20200337905 | Earl et al. | Oct 2020 | A1 |
| 20200337906 | Long et al. | Oct 2020 | A1 |
| 20200337908 | Long et al. | Oct 2020 | A1 |
| 20200338228 | Kharkar et al. | Oct 2020 | A1 |
| 20200338243 | Harrison et al. | Oct 2020 | A1 |
| Number | Date | Country |
|---|---|---|
| 3187204 | Jul 2017 | EP |
| 3556407 | Oct 2019 | EP |
| 3569260 | Nov 2019 | EP |
| 3643328 | Apr 2020 | EP |
| 3643330 | Apr 2020 | EP |
| 3643331 | Apr 2020 | EP |
| 3669838 | Jun 2020 | EP |
| 3669843 | Jun 2020 | EP |
| 3669844 | Jun 2020 | EP |
| 2579211 | Jun 2020 | GB |
| 2579368 | Jun 2020 | GB |
| 2005018543 | Mar 2005 | WO |
| 2011121394 | Oct 2011 | WO |
| 2011135284 | Nov 2011 | WO |
| 2011144888 | Nov 2011 | WO |
| 2013015827 | Jan 2013 | WO |
| 2013126049 | Aug 2013 | WO |
| 2014014842 | Jan 2014 | WO |
| 2015145117 | Oct 2015 | WO |
| 2015173546 | Nov 2015 | WO |
| 2016141450 | Sep 2016 | WO |
| 2017016974 | Feb 2017 | WO |
| 2017125250 | Jul 2017 | WO |
| 2018029231 | Feb 2018 | WO |
| 2018094061 | May 2018 | WO |
| 2018162613 | Sep 2018 | WO |
| 2018163093 | Sep 2018 | WO |
| 2018189265 | Oct 2018 | WO |
| 2018226667 | Dec 2018 | WO |
| 2018227144 | Dec 2018 | WO |
| 2018231825 | Dec 2018 | WO |
| 2018236648 | Dec 2018 | WO |
| 2019002085 | Jan 2019 | WO |
| 2019012068 | Jan 2019 | WO |
| 2019012069 | Jan 2019 | WO |
| 2019022493 | Jan 2019 | WO |
| 2019027933 | Feb 2019 | WO |
| 2019038548 | Feb 2019 | WO |
| 2019038549 | Feb 2019 | WO |
| 2019040656 | Feb 2019 | WO |
| 2019050855 | Mar 2019 | WO |
| 2019058373 | Mar 2019 | WO |
| 2019073326 | Apr 2019 | WO |
| 2019083563 | May 2019 | WO |
| 2019083868 | May 2019 | WO |
| 2019086911 | May 2019 | WO |
| 2019091150 | May 2019 | WO |
| 2019094147 | May 2019 | WO |
| 2019096828 | May 2019 | WO |
| 2019113275 | Jun 2019 | WO |
| 2019113623 | Jun 2019 | WO |
| 2019191590 | Oct 2019 | WO |
| 2019193141 | Oct 2019 | WO |
| 2019193333 | Oct 2019 | WO |
| 2019199389 | Oct 2019 | WO |
| 2019199596 | Oct 2019 | WO |
| 2019199687 | Oct 2019 | WO |
| 2019199798 | Oct 2019 | WO |
| 2019199849 | Oct 2019 | WO |
| 2019200035 | Oct 2019 | WO |
| 2019215572 | Nov 2019 | WO |
| 2019219613 | Nov 2019 | WO |
| 2019234365 | Dec 2019 | WO |
| 2020005062 | Jan 2020 | WO |
| 2020005344 | Jan 2020 | WO |
| 2020005536 | Jan 2020 | WO |
| 2020005546 | Jan 2020 | WO |
| 2020005577 | Jan 2020 | WO |
| 2020007429 | Jan 2020 | WO |
| 2020011691 | Jan 2020 | WO |
| 2020014178 | Jan 2020 | WO |
| 2020014310 | Jan 2020 | WO |
| 2020018300 | Jan 2020 | WO |
| 2020026061 | Feb 2020 | WO |
| 2020026144 | Feb 2020 | WO |
| 2020033351 | Feb 2020 | WO |
| 2020035811 | Feb 2020 | WO |
| 2020043665 | Mar 2020 | WO |
| 2020044237 | Mar 2020 | WO |
| 2020046443 | Mar 2020 | WO |
| 2020047255 | Mar 2020 | WO |
| 2020049038 | Mar 2020 | WO |
| 2020055945 | Mar 2020 | WO |
| 2020056014 | Mar 2020 | WO |
| 2020056182 | Mar 2020 | WO |
| 2020065531 | Apr 2020 | WO |
| 2020070231 | Apr 2020 | WO |
| 2020074512 | Apr 2020 | WO |
| 2020078993 | Apr 2020 | WO |
| 2020079009 | Apr 2020 | WO |
| 2020079330 | Apr 2020 | WO |
| 2020081259 | Apr 2020 | WO |
| 2020081391 | Apr 2020 | WO |
| 2020092598 | May 2020 | WO |
| 2020136555 | Jul 2020 | WO |
| 2020141059 | Jul 2020 | WO |
| 2020144347 | Jul 2020 | WO |
| 2020150548 | Jul 2020 | WO |
| 2020159675 | Aug 2020 | WO |
| 2020159677 | Aug 2020 | WO |
| 2020159678 | Aug 2020 | WO |
| 2020159823 | Aug 2020 | WO |
| 2020159859 | Aug 2020 | WO |
| 2020159892 | Aug 2020 | WO |
| 2020161086 | Aug 2020 | WO |
| 2020173665 | Sep 2020 | WO |
| 2020173760 | Sep 2020 | WO |
| 2020174264 | Sep 2020 | WO |
| 2020174510 | Sep 2020 | WO |
| 2020182887 | Sep 2020 | WO |
| 2020185810 | Sep 2020 | WO |
| 2020197759 | Oct 2020 | WO |
| 2020197760 | Oct 2020 | WO |
| 2020198484 | Oct 2020 | WO |
| 2020201879 | Oct 2020 | WO |
| 2020213998 | Oct 2020 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20210196525 A1 | Jul 2021 | US |
